IPF Partners Grants Up to EUR 30 Million Debt Funding to Faron to Advance and Accelerate Pipeline

Faron Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, announces that it has entered into a secured debt agreement with IPF Partners to advance and accelerate its pipeline programs.